A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: An Eastern Cooperative Oncology Group study (E3296)

Jordan D. Berlin*, Sudeshna Adak, David J. Vaughn, David Flinker, Lawrence Blaszkowsky, Jules E. Harris, Al Bowen Benson

*Corresponding author for this work

Research output: Contribution to journalArticle

69 Scopus citations

Abstract

Gemcitabine has recently been compared favorably to 5-fluorouracil (5-FU) as the standard chemotherapy for advanced pancreas cancer. Based on phase I data that combining gemcitabine with 5-FU is safe and has evidence for clinical activity, a phase II trial was conducted by the Eastern Cooperative Oncology Group (ECOG). Patients with metastatic disease, good performance status and organ function were eligible and enrolled after providing informed consent. Patients were given gemcitabine (1000 mg/m2) followed by 5-FU (600 mg/m2) weekly for 3 weeks of every 4. Of 37 patients enrolled over a 3-month period, 36 were eligible. Partial responses were seen in 5 patients (14%), Median survival was 4.4 months with a 1-year survival rate of 8.6%, A randomized trial of the combination of 5-FU and gemcitabine versus gemcitabine alone is currently accruing patients in ECOG. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish (US)
Pages (from-to)215-218
Number of pages4
JournalONCOLOGY
Volume58
Issue number3
DOIs
StatePublished - Apr 2000

Keywords

  • 5-Fluorouracil
  • Gemcitabine
  • Pancreas cancer
  • Phase II trial

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: An Eastern Cooperative Oncology Group study (E3296)'. Together they form a unique fingerprint.

  • Cite this